Literature DB >> 28771321

Activity-Based Detection of Consumption of Synthetic Cannabinoids in Authentic Urine Samples Using a Stable Cannabinoid Reporter System.

Annelies Cannaert1, Florian Franz2, Volker Auwärter2, Christophe P Stove1.   

Abstract

Synthetic cannabinoids (SCs) continue to be the largest group of new psychoactive substances (NPS) monitored by the European Monitoring Center of Drugs and Drugs of Abuse (EMCDDA). The identification and subsequent prohibition of single SCs has driven clandestine chemists to produce analogues of increasing structural diversity, intended to evade legislation. That structural diversity, combined with the mostly unknown metabolic profiles of these new SCs, poses a big challenge for the conventional targeted analytical assays, as it is difficult to screen for "unknown" compounds. Therefore, an alternative screening method, not directly based on the structure but on the activity of the SC, may offer a solution for this problem. We generated stable CB1 and CB2 receptor activation assays based on functional complementation of a split NanoLuc luciferase and used these to test an expanded set of recent SCs (UR-144, XLR-11, and their thermal degradation products; AB-CHMINACA and ADB-CHMINACA) and their major phase I metabolites. By doing so, we demonstrate that several major metabolites of these SCs retain their activity at the cannabinoid receptors. These active metabolites may prolong the parent compound's psychotropic and physiological effects and may contribute to the toxicity profile. Utility of the generated stable cell systems as a first-line screening tool for SCs in urine was also demonstrated using a relatively large set of authentic urine samples. Our data indicate that the stable CB reporter assays detect CB receptor activation by extracts of urine in which SCs (or their metabolites) are present at low- or subnanomolar (ng/mL) level. Hence, the developed assays do not only allow activity profiling of SCs and their metabolites, it may also serve as a screening tool, complementing targeted and untargeted analytical assays and preceding analytical (mass spectrometry based) confirmation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28771321     DOI: 10.1021/acs.analchem.7b02552

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  14 in total

Review 1.  Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication.

Authors:  Katharina Elisabeth Grafinger; Matthias E Liechti; Evangelia Liakoni
Journal:  Br J Clin Pharmacol       Date:  2019-12-17       Impact factor: 4.335

2.  Should NPS be included in workplace drug testing?

Authors:  Alberto Salomone; Joseph J Palamar; Marco Vincenti
Journal:  Drug Test Anal       Date:  2020-01-23       Impact factor: 3.345

3.  Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Ryan J McKinnie; Richard C Kevin; Iain S McGregor; Mark L Trudell; Jenny L Wiley; Brian F Thomas
Journal:  J Pharmacol Exp Ther       Date:  2018-12-14       Impact factor: 4.030

4.  Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA.

Authors:  Eric Sparkes; Elizabeth A Cairns; Richard C Kevin; Felcia Lai; Katharina Elisabeth Grafinger; Shuli Chen; Marie H Deventer; Ross Ellison; Rochelle Boyd; Lewis J Martin; Iain S McGregor; Roy R Gerona; David E Hibbs; Volker Auwärter; Michelle Glass; Christophe Stove; Samuel D Banister
Journal:  RSC Med Chem       Date:  2021-10-25

5.  Linking in vitro and ex vivo CB1 activity with serum concentrations and clinical features in 5F-MDMB-PICA users to better understand SCRAs and their metabolites.

Authors:  Liesl K Janssens; Simon Hudson; David M Wood; Caitlin Wolfe; Paul I Dargan; Christophe P Stove
Journal:  Arch Toxicol       Date:  2022-08-12       Impact factor: 6.168

Review 6.  Detection of the Synthetic Cannabinoids AB-CHMINACA, ADB-CHMINACA, MDMB-CHMICA, and 5F-MDMB-PINACA in Biological Matrices: A Systematic Review.

Authors:  Elisabet Navarro-Tapia; Jana Codina; Víctor José Villanueva-Blasco; Óscar García-Algar; Vicente Andreu-Fernández
Journal:  Biology (Basel)       Date:  2022-05-23

7.  Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds.

Authors:  Elise Wouters; Jolien Walraed; Michael Joseph Robertson; Max Meyrath; Martyna Szpakowska; Andy Chevigné; Georgios Skiniotis; Christophe Stove
Journal:  ACS Pharmacol Transl Sci       Date:  2019-11-04

8.  Assessment of biased agonism at the A3 adenosine receptor using β-arrestin and miniGαi recruitment assays.

Authors:  Eline Pottie; Dilip K Tosh; Zhan-Guo Gao; Kenneth A Jacobson; Christophe P Stove
Journal:  Biochem Pharmacol       Date:  2020-03-26       Impact factor: 5.858

9.  Activity-Based Detection and Bioanalytical Confirmation of a Fatal Carfentanil Intoxication.

Authors:  Annelies Cannaert; Lars Ambach; Peter Blanckaert; Christophe P Stove
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

10.  Toxicokinetics and toxicodynamics of the fentanyl homologs cyclopropanoyl-1-benzyl-4´-fluoro-4-anilinopiperidine and furanoyl-1-benzyl-4-anilinopiperidine.

Authors:  Tanja M Gampfer; Lea Wagmann; Yu Mi Park; Annelies Cannaert; Jennifer Herrmann; Svenja Fischmann; Folker Westphal; Rolf Müller; Christophe P Stove; Markus R Meyer
Journal:  Arch Toxicol       Date:  2020-04-05       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.